Boosting the Economy and Driving Innovation
Between 1998 and 2018, NCI SBIR/STTR awardees fueled $26.1 billion in economic output, 100,000+ jobs, and breakthrough cancer technologies.
Learn MoreLatest Opportunities with SBIR
-
NCI SBIR/STTR Commercialization Readiness Pilot (CRP) ProgramThe CRP Program helps small businesses with NCI SBIR/STTR projects bridge the gap between late-stage research and commercialization. The application deadline is September 8, 2026.
-
NCI SBIR/STTR Investor Initiatives Showcase CompaniesThe NCI SBIR/STTR Investor Initiatives Program is specifically designed to connect funded companies with potential investors and strategic partners. Check out the 2026-2027 showcase companies to learn more.
-
NCI SBIR/STTR Strategic Breakthrough AwardsThe NCI SBIR/STTR Phase IIB Strategic Breakthrough Award is a first-of-its-kind funding mechanism designed to accelerate late-stage clinical development of technologies addressing pediatric and rare cancers. The application deadline is September 8, 2026.
Success Story: Illumina
Biomedical researchers at Illumina are developing next-generation tools to analyze genetic variation and function on a massive scale. Illumina used NCI SBIR funding to develop their next generation sequencing technology.
Learn More
Why SBIR?